May 2023 in “Dermatology and therapy” This study aims to provide a practical guide for managing common causes of madarosis, highlighting the need to identify underlying causes to ensure effective treatment for eyelash and eyebrow loss.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
6 citations
,
January 2023 in “Annals of Dermatology” This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.
4 citations
,
November 2022 in “Frontiers in Medicine” This study found that people with alopecia areata have a higher likelihood of experiencing anxiety and depression, and a moderate negative impact on their quality of life compared to healthy individuals.
37 citations
,
August 2022 in “Frontiers in pharmacology” This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.
148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
6 citations
,
March 2021 in “Journal of the American Academy of Dermatology” This study found that the Brigham Eyelash Tool for Alopecia (BELA) is a reliable measure for assessing eyelash loss in alopecia areata patients, demonstrating high inter- and intrarater reliability.
4 citations
,
November 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.
23 citations
,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.
56 citations
,
August 2020 in “American Journal of Clinical Dermatology” This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.
13 citations
,
April 2020 in “Dermatology and therapy” This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.
37 citations
,
December 2019 in “Giornale italiano di dermatologia e venereologia” This Italian guideline discusses the diagnosis and treatment of alopecia areata but reports no new clinical trial results; the authors highlight the need for well-designed studies.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.
41 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.
164 citations
,
November 1989 in “Clinical and Experimental Dermatology” This retrospective study found that juvenile alopecia areata is more severe and has a worse prognosis than maturity-onset alopecia areata.
